Round out your CMHC Live Online educational experience by attending Professional Medical Education/Product Theater symposia focused on novel therapies. These non-certified activities are planned solely by the sponsoring organizations/companies.
WEDNESDAY, OCTOBER 21, 2020 · 12:00 – 1:00 PM Eastern Time
Presenters: Eden Miller, DO; Kris Vijay, MD, MS, FACP, FACC, FNLA, FCRS, FHFSA
Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc and Lilly USA, LLC.
Information to come.
WEDNESDAY, OCTOBER 21, 2020 · 6:30 – 7:30 PM Eastern Time
Presenter: Eliot A. Brinton, MD, FAHA, FNLA, FACE
Sponsored by Esperion Therapeutics.
This session will cover the following information:
THURSDAY, OCTOBER 22, 2020 · 12:25 – 1:25 PM Eastern Time
Presenter: Yehuda Handelsman, MD
Sponsored by Novartis.
This program highlights the burden of cardiovascular disease in patients with diabetes who have an elevated risk of ASCVD and cardiovascular events. The mechanistic role of elevated LDL-C in ASCVD progression and the importance of lowering LDL-C levels is emphasized, and the use of LDL-C–lowering therapies to reduce risk in patients with diabetes is described, in context with currently published guidelines.
THURSDAY, OCTOBER 22, 2020 · 5:20 – 6:20 PM Eastern Time
Presenter: Matthew Budoff, MD, FACC, FAHA
Sponsored by Amarin Pharma, Inc.
There is an urgency to treat Persistent Cardiovascular Risk (P-CVR) as it remains high despite statin-based standard-of-care therapy in patients with elevated triglycerides. In this program, we will review data from a practice changing trial that provides a groundbreaking therapeutic option to elevate the current standard of care.
FRIDAY, OCTOBER 23, 2020 · 12:00 – 1:00 PM Eastern Time
Presenter: John E. Anderson, MD
Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.
The objective of this program is to communicate the importance of addressing cardiovascular risk in patients with type 2 diabetes. The program will cover data on prevalence, morbidity, mortality, and intensive versus conventional glucose lowering on macrovascular complications. In addition, the program will review guidance from leading medical associations that is based upon completed cardiovascular outcome trials of antihyperglycemic medications in patients with type 2 diabetes.